Clinical characterization and economic impact evaluation of anti- HCV DAA treatment failure: real life data fromthe Italian Platform for the Study of Viral Hepatitis Therapies (PITER)

L. A. Kondili1;on behalf of PITER Collaborating Group;A. Di Leo2;A. Iannone2;T. Santantonio;A. Giammario3;G. Raimondo4;R. Filomia4;C. Coppola5;D. Amoruso5;P. Blanc6;B. Del Pin6;L. Chemello7;L. Cavalletto7;F. Morisco8;L. Donnarumma8;M. G. Rumi9;A. Gasbarrini10;M. Siciliano11;M. Massari12;R. Corsini12;M. R. Brunetto13;B. Coco13;S. Madonia14;A. L. Zignego15;M. Monti15;F. P. Russo7;A. Zanetto7;M. Persico16;M. Masarone16;E. Villa17;V. Bernabucci17;G. Taliani18;E. Biliotti18;L. Chessa19;M. C. Pasetto19;P. Andreone20;M. Margotti20;G. B. Gaeta21;V. Rizzo21;D. Ieluzzi22;G. Borgia8;E. Zappulo8;V. Calvaruso23;S. Petta23;F. R. Rolli10;L. Falzano1;S. Rosato1;M. Ruggeri10

2017-01-01